Stock Scorer

Bioadaptives, Inc. (BDPT)

Bioadaptives, Inc. reported revenue of 5K USD for the quarter ending 30 June 2026, up 55.0% from 3.2K a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 5K +55.0%
Gross Profit Q2 '26 · ending 30 June 2026 4.2K +298.9%
Operating Income Q2 '26 · ending 30 June 2026 -197.2K —
Net Income Q2 '26 · ending 30 June 2026 150.1K —
Cost of Revenue Q2 '26 · ending 30 June 2026 748 -65.3%
Operating Cash Flow Q2 '26 · ending 30 June 2026 -44.4K —
Free Cash Flow Q4 '25 · ending 31 December 2025 -155.8K —
Shares Outstanding Q2 '26 · ending 30 June 2026 281.2M +3007.6%
EPS Q2 '26 · ending 30 June 2026 -0.12 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 18.3K-1M-1.6M-534K
20242024-12-31 12.7K-602.1K-899.2K-249.5K
20232023-12-31 28.6K-228.9K-712.5K—
20222022-12-31 17.2K-421.9K-895.6K—
20212021-12-31 19.8K—-1M—
20202020-12-31 16.3K—-847.2K—
20192019-12-31 9.9K—-238.9K—

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-305K
Q1 '262026-03-315.5K
Q4 '252025-12-3110.4K
Q3 '252025-09-304.6K
Q2 '252025-06-303.2K
Q1 '252025-03-310
Q4 '242024-12-310
Q3 '242024-09-300
Q2 '242024-06-30675
Q1 '242024-03-3112K
Q4 '232023-12-317.2K
Q3 '232023-09-3015.6K
Q2 '232023-06-302.3K
Q1 '232023-03-313.4K
Q4 '222022-12-314K
Q3 '222022-09-303.3K
Q2 '222022-06-304.3K
Q1 '222022-03-315.5K
Q4 '212021-12-313.9K
Q3 '212021-09-305.3K

Gross Profit Quarterly

PeriodEndingGross Profit
Q2 '262026-06-304.2K
Q1 '262026-03-314.1K
Q4 '252025-12-317.6K
Q3 '252025-09-303.9K
Q2 '252025-06-301.1K
Q1 '252025-03-310
Q4 '242024-12-310
Q3 '242024-09-300
Q2 '242024-06-30429
Q1 '242024-03-313.6K
Q4 '232023-12-312.7K
Q3 '232023-09-304.7K
Q2 '232023-06-301.5K
Q1 '232023-03-312K
Q4 '222022-12-311K
Q3 '222022-09-302K
Q2 '222022-06-302.2K
Q1 '222022-03-311.9K
Q4 '212021-12-311.1K
Q3 '212021-09-303.1K

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-197.2K
Q1 '262026-03-31-198.2K
Q4 '252025-12-31-248.1K
Q3 '252025-09-30-265.7K
Q2 '252025-06-30-279.2K
Q1 '252025-03-31-249.1K
Q4 '242024-12-31-337.3K
Q3 '242024-09-30-121.9K
Q2 '242024-06-30-93K
Q1 '242024-03-31-49.8K
Q4 '232023-12-31-61.8K
Q3 '232023-09-30-92.2K
Q2 '232023-06-30-55.9K
Q1 '232023-03-31-19K
Q3 '162016-09-30-26.3K
Q2 '162016-06-30-33.2K
Q1 '162016-03-31-80.9K
Q4 '152015-12-31-48.5K
Q3 '152015-09-30-40.1K
Q2 '152015-06-30-109.4K

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30150.1K
Q1 '262026-03-31-111.1K
Q4 '252025-12-31-823.3K
Q3 '252025-09-30-379.5K
Q2 '252025-06-30-157.9K
Q1 '252025-03-31-197.1K
Q4 '242024-12-31-371.8K
Q3 '242024-09-30-37.6K
Q2 '242024-06-30-183K
Q1 '242024-03-31-306.7K
Q4 '232023-12-31-268.3K
Q3 '232023-09-30-13.1K
Q2 '232023-06-30-143.9K
Q1 '232023-03-31-287.2K
Q4 '222022-12-31-28.3K
Q3 '222022-09-30-276.3K
Q2 '222022-06-30-223.8K
Q1 '222022-03-31-367.1K
Q4 '212021-12-31-214.3K
Q3 '212021-09-30-34.5K

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262026-06-30748
Q1 '262026-03-311.4K
Q4 '252025-12-312.8K
Q3 '252025-09-30781
Q2 '252025-06-302.2K
Q1 '252025-03-310
Q4 '242024-12-310
Q3 '242024-09-300
Q2 '242024-06-30246
Q1 '242024-03-318.4K
Q4 '232023-12-314.5K
Q3 '232023-09-3011K
Q2 '232023-06-30849
Q1 '232023-03-311.4K
Q4 '222022-12-313K
Q3 '222022-09-301.3K
Q2 '222022-06-302.2K
Q1 '222022-03-313.6K
Q4 '212021-12-312.7K
Q3 '212021-09-302.2K

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-44.4K
Q1 '262026-03-31-84.8K
Q4 '252025-12-31-155.8K
Q3 '252025-09-30-151.3K
Q2 '252025-06-30-111K
Q1 '252025-03-31-97.9K
Q4 '242024-12-31-100.5K
Q3 '242024-09-30-56.3K
Q2 '242024-06-30-51.5K
Q1 '242024-03-31-41.2K
Q4 '232023-12-31-91.3K
Q3 '232023-09-30-56.1K
Q2 '232023-06-30-56.9K
Q1 '232023-03-31-19.5K
Q4 '222022-12-31-27.5K
Q3 '222022-09-30-61.5K
Q2 '222022-06-30-77.1K
Q1 '222022-03-31-61.2K
Q4 '212021-12-31-35.4K
Q3 '212021-09-30-33.2K

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q4 '252025-12-31-155.8K
Q3 '252025-09-30-151.3K
Q4 '242024-12-31-100.5K
Q3 '242024-09-30-56.3K
Q4 '142014-12-31-45.7K
Q3 '142014-09-3010.5K

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30281.2M
Q1 '262026-03-3112M
Q3 '252025-09-3010.2M
Q2 '252025-06-309.5M
Q1 '252025-03-319M
Q3 '242024-09-308.2M
Q2 '242024-06-303M
Q1 '242024-03-317.7M
Q3 '232023-09-30730M
Q1 '202020-03-3118.9M
Q1 '192019-03-3122.6M
Q3 '142014-09-3012.6M
Q2 '142014-06-3012.6M
Q1 '142014-03-3112.1M
Q3 '132013-09-3010M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-0.12
Q1 '262026-03-31-0.14
Q4 '252025-12-31-0.15
Q3 '252025-09-30-0.19
Q2 '252025-06-30-0.15
Q1 '252025-03-31-0.07
Q4 '242024-12-31-0.09
Q3 '242024-09-30-0.10
Q2 '242024-06-30-0.10
Q1 '212021-03-31-0.05
Q4 '202020-12-31-0.04
Q3 '202020-09-30-0.03
Q2 '202020-06-30-0.03
Q1 '202020-03-31-0.02
Q4 '192019-12-31-0.01
Q3 '192019-09-30-0.03
Q2 '192019-06-30-0.07
Q1 '192019-03-31-0.08
Q4 '182018-12-31-0.08
Q3 '162016-09-30-0.02